CORT
Corcept Therapeutics Incorporated NASDAQ Listed Apr 14, 2004$51.05
Mkt Cap $5.5B
52w Low $28.66
35.9% of range
52w High $91.00
50d MA $40.28
200d MA $60.40
P/E (TTM)
54.1x
EV/EBITDA
51.2x
P/B
8.2x
Debt/Equity
0.0x
ROE
15.4%
P/FCF
25.5x
RSI (14)
—
ATR (14)
—
Beta
0.25
50d MA
$40.28
200d MA
$60.40
Avg Volume
1.7M
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
149 Commonwealth Drive · Menlo Park, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.11 | -0.30 | -176.5% | 46.52 | +4.2% | +10.5% | +10.9% | +10.3% | +12.1% | +9.7% | — |
| Feb 24, 2026 | AMC | 0.33 | 0.20 | -39.4% | 36.48 | +3.2% | -0.7% | -1.9% | -2.1% | -1.4% | -3.3% | — |
| Nov 4, 2025 | AMC | 0.18 | 0.16 | -11.1% | 71.10 | -5.8% | +7.8% | +2.8% | +3.7% | +6.2% | +11.1% | — |
| Jul 31, 2025 | AMC | 0.23 | 0.29 | +26.1% | 67.17 | -3.6% | +2.7% | +6.8% | +4.9% | +5.0% | +6.4% | — |
| May 5, 2025 | AMC | 0.17 | 0.17 | +0.0% | 73.94 | -9.1% | -4.3% | -4.7% | -3.5% | -5.0% | -2.4% | — |
| Feb 26, 2025 | AMC | 0.37 | 0.26 | -29.7% | 63.37 | -3.7% | -5.6% | -4.4% | -6.8% | -11.6% | -12.4% | — |
| Oct 30, 2024 | AMC | 0.28 | 0.41 | +46.4% | 46.89 | -1.9% | +4.4% | +1.6% | +6.8% | +11.2% | +15.7% | — |
| Jul 29, 2024 | AMC | 0.23 | 0.32 | +39.1% | 36.53 | +5.1% | -1.1% | +5.9% | +3.9% | -3.4% | -5.5% | — |
| May 1, 2024 | AMC | 0.22 | 0.25 | +13.6% | 23.88 | +10.5% | +4.9% | +2.7% | +0.4% | +2.5% | +6.4% | — |
| Feb 15, 2024 | AMC | 0.26 | 0.28 | +7.7% | 24.46 | +6.3% | -7.2% | -7.7% | -11.4% | -6.0% | -8.2% | — |
| Nov 1, 2023 | AMC | 0.22 | 0.28 | +27.3% | 28.09 | -0.8% | -10.0% | -8.8% | -7.8% | -8.4% | -8.3% | — |
| Aug 2, 2023 | AMC | 0.15 | 0.25 | +66.7% | 25.01 | +4.0% | +24.9% | +24.7% | +20.9% | +21.9% | +20.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.52 | $48.48 | +4.2% | +10.5% | +10.9% | +10.3% | +12.1% | +9.7% |
| Mar 26 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $40.47 | $38.76 | -4.2% | -4.8% | -7.1% | -5.8% | -0.4% | +3.7% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $40.47 | $38.76 | -4.2% | -4.8% | -7.1% | -5.8% | -0.4% | +3.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.82 | $34.15 | +1.0% | +19.7% | +13.9% | +11.2% | +12.7% | +19.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.48 | $37.65 | +3.2% | -0.7% | -1.9% | -2.1% | -1.4% | -3.3% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.24 | $33.97 | -0.8% | +1.7% | +3.2% | +6.5% | +5.8% | +4.5% |
| Jan 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +10.5% | +11.9% | +11.0% | +8.0% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +10.5% | +11.9% | +11.0% | +8.0% |
| Jan 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | +0.4% | +2.8% | +6.3% | +5.0% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | +0.4% | +2.8% | +6.3% | +5.0% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.71 | $78.59 | +1.1% | +3.3% | +2.7% | +2.2% | +2.7% | +3.9% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $78.69 | $79.71 | +1.3% | -0.1% | -4.2% | -6.4% | -7.3% | -7.8% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.36 | $87.54 | -0.9% | -16.3% | -19.0% | -18.4% | -13.1% | -10.1% |
| Sep 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $83.84 | $83.38 | -0.5% | -1.3% | +0.0% | +0.1% | -0.9% | +0.5% |
| Sep 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $71.73 | $72.45 | +1.0% | -0.2% | +3.6% | +1.6% | -3.1% | -0.6% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $67.17 | $64.75 | -3.6% | +2.7% | +6.8% | +4.9% | +5.0% | +6.4% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $67.17 | $64.75 | -3.6% | +2.7% | +6.8% | +4.9% | +5.0% | +6.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.94 | $67.24 | -9.1% | -4.3% | -4.7% | -3.5% | -5.0% | -2.4% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $83.81 | $79.16 | -5.5% | -5.3% | -11.2% | -10.9% | -15.9% | -12.9% |
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $114.22 | $114.68 | +0.4% | -19.5% | -26.6% | -30.5% | -34.8% | -34.6% |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $54.63 | $94.93 | +73.8% | +109.1% | +68.3% | +53.4% | +45.3% | +36.3% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.63 | $94.93 | +73.8% | +109.1% | +68.3% | +53.4% | +45.3% | +36.3% |
| Feb 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $63.37 | $61.00 | -3.7% | -5.6% | -4.4% | -6.8% | -11.6% | -12.4% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.37 | $61.00 | -3.7% | -5.6% | -4.4% | -6.8% | -11.6% | -12.4% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.54 | $67.92 | +0.6% | +0.8% | +3.9% | +9.0% | +7.7% | +7.5% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.04 | $68.06 | +0.0% | -0.0% | -0.7% | +0.1% | +3.1% | +8.2% |
| Jan 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $61.53 | $63.33 | +2.9% | +13.6% | +8.8% | +8.2% | +8.7% | +11.2% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.89 | $45.99 | -1.9% | +4.4% | +1.6% | +6.8% | +11.2% | +15.7% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.17 | $47.79 | +1.3% | +5.5% | +4.1% | +3.7% | +1.9% | +0.1% |
| Sep 30 | Truist | Maintains | Buy → Buy | — | $43.93 | $44.37 | +1.0% | +5.3% | +6.4% | +4.4% | +2.5% | +3.4% |
| Sep 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.71 | $40.30 | +1.5% | +6.4% | +3.0% | +6.4% | +8.2% | +10.8% |
| Jul 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.12 | $37.24 | +3.1% | +7.1% | +5.0% | -2.3% | -4.5% | -5.3% |
| Jul 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.53 | $38.39 | +5.1% | -1.1% | +5.9% | +3.9% | -3.4% | -5.5% |
| Jul 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.53 | $38.39 | +5.1% | -1.1% | +5.9% | +3.9% | -3.4% | -5.5% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.53 | $38.39 | +5.1% | -1.1% | +5.9% | +3.9% | -3.4% | -5.5% |
| Jul 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.49 | $32.49 | +0.0% | +0.6% | -2.9% | -6.1% | -7.4% | -9.2% |
| Jun 17 | Truist | Maintains | Buy → Buy | — | $28.97 | $29.11 | +0.5% | -1.3% | -2.8% | +1.5% | +3.7% | +5.6% |
| Jun 4 | Truist | Maintains | Buy → Buy | — | $31.30 | $31.93 | +2.0% | +5.0% | +10.0% | +10.2% | +6.4% | +2.0% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.61 | $31.50 | -0.3% | -0.3% | -1.3% | -4.6% | -1.0% | +4.0% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.88 | $26.39 | +10.5% | +4.9% | +2.7% | +0.4% | +2.5% | +6.4% |
| May 2 | Truist | Maintains | Buy → Buy | — | $23.88 | $26.39 | +10.5% | +4.9% | +2.7% | +0.4% | +2.5% | +6.4% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.30 | $22.76 | +2.1% | +3.1% | +0.8% | -0.4% | +2.2% | +4.8% |
| Feb 16 | Truist | Maintains | Buy → Buy | — | $24.46 | $26.00 | +6.3% | -7.2% | -7.7% | -11.4% | -6.0% | -8.2% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.48 | $22.11 | -31.9% | -25.6% | -21.8% | -22.0% | -25.2% | -15.5% |
| Dec 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $27.85 | $28.19 | +1.2% | +8.0% | +7.1% | +6.8% | +9.7% | +12.1% |
| Nov 6 | Truist | Upgrade | Hold → Buy | — | $25.62 | $26.72 | +4.3% | +1.1% | +0.5% | +0.5% | -2.8% | -2.3% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.09 | $27.86 | -0.8% | -10.0% | -8.8% | -7.8% | -8.4% | -8.3% |
| Oct 2 | Truist | Maintains | Hold → Hold | — | $27.25 | $27.24 | -0.0% | -3.5% | -3.9% | -4.9% | -2.8% | -3.1% |
| Aug 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $31.77 | $31.81 | +0.1% | -0.1% | +1.4% | +3.3% | +3.5% | +3.0% |
| Aug 3 | Truist | Maintains | Hold → Hold | — | $25.01 | $26.00 | +4.0% | +24.9% | +24.7% | +20.9% | +21.9% | +20.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Guyer William | Chief Development Officer | Sell | 20,000 | $51.83 | $1.0M | 2,231 | — | — |
| May 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | Sell | 40,000 | $50.10 | $2.0M | 2,878,326 | +1.60% | — |
8-K · 7.01
! Medium
Corcept Therapeutics Incorporated -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q1 2026 financial results and corporate updates via press release, providing investors with recent performance metrics and strategic developments.
Apr 30
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K
Unknown — 8-K Filing
Corcept Therapeutics gained FDA approval for Lifyorli in a new oncology indication, expanding its market opportunity beyond Cushing's syndrome and potentially driving significant revenue growth from this first-in-class selective glucocorticoid receptor antagonist.
Mar 25
8-K · 7.01
! Medium
Corcept Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q4 2025 financial results and corporate updates via press release, providing investors with recent performance metrics and forward guidance for the pharmaceutical company.
Feb 24
8-K
Corcept Therapeutics Inc. -- 8-K Filing
Corcept Therapeutics lost a Federal District Court appeal in New Jersey, upholding a December 2023 verdict that may have negative financial or legal implications for the company's operations or intellectual property.
Feb 19
Data updated apr 25, 2026 2:42am
· Source: massive.com